INDICATION AND IMPORTANT SAFETY INFORMATION
TOBI® Podhaler® (Tobramycin Inhalation Powder) 28 mg per capsule is indicated for the management of cystic fibrosis patients with Pseudomonas aeruginosa.  ...More

Resources

Resources available to you to support your patients.

PodCare+ Enrollment Form

Sign up your patients for the TOBI Podhaler patient support program

Download

Addressing Cough

Helpful information regarding potential cough side effect

Download

How To Use Guide

Step By Step Instructions on how to administer TOBI Podhaler.

Download

Healthcare Provider Brochure

Learn more about TOBI Podhaler

Download

Share

To share this website with other health care professionals, please choose your email service provider:

This site is intended for US healthcare professionals. By clicking "continue" you acknowledge that you are a US healthcare professional.

INDICATION AND IMPORTANT SAFETY INFORMATION

INDICATION

TOBI® Podhaler® (Tobramycin Inhalation Powder) 28 mg per capsule is indicated for the management of cystic fibrosis patients with Pseudomonas aeruginosa.

Safety and efficacy have not been demonstrated in patients under the age of 6 years, patients with forced expiratory volume in 1 second (FEV1) <25% or >80% predicted, or patients colonized with Burkholderia cepacia.